Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Ceftolozane-tazobactam activity against phylogenetically diverse Clostridium difficile strains.

Literature DB >> 26282409

Ceftolozane-tazobactam activity against phylogenetically diverse Clostridium difficile strains.

Mark D Gonzalez¹, Meghan A Wallace¹, Tiffany Hink², Erik R Dubberke², Carey-Ann D Burnham³.

Abstract

Ceftolozane-tazobactam (C/T) is approved for the treatment of complicated intra-abdominal and urinary tract infections and has varied activity against anaerobic bacteria. Here, we evaluate the activity of C/T against a phylogenetically diverse collection of Clostridium difficile isolates and report uniformly high MICs (≥256 μg/ml) to C/T.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2015 PMID： 26282409 PMCID： PMC4604413 DOI： 10.1128/AAC.01670-15

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

Keyword Cloud
References

19 in total

1. Development and evaluation of a novel, semiautomated Clostridium difficile typing platform.

Authors: Lars F Westblade; Robin R Chamberland; Duncan MacCannell; Rachel Collins; Erik R Dubberke; W Michael Dunne; Carey-Ann D Burnham
Journal: J Clin Microbiol Date: 2012-11-21 Impact factor: 5.948

Review 2. The changing epidemiology of Clostridium difficile infections.

Authors: J Freeman; M P Bauer; S D Baines; J Corver; W N Fawley; B Goorhuis; E J Kuijper; M H Wilcox
Journal: Clin Microbiol Rev Date: 2010-07 Impact factor: 26.132

3. Antimicrobial-resistant strains of Clostridium difficile from North America.

Authors: Fred C Tenover; Isabella A Tickler; David H Persing
Journal: Antimicrob Agents Chemother Date: 2012-03-12 Impact factor: 5.191

4. Impact of clinical symptoms on interpretation of diagnostic assays for Clostridium difficile infections.

Authors: Erik R Dubberke; Zhuolin Han; Linda Bobo; Tiffany Hink; Brenda Lawrence; Susan Copper; Joan Hoppe-Bauer; Carey-Ann D Burnham; William Michael Dunne
Journal: J Clin Microbiol Date: 2011-06-22 Impact factor: 5.948

5. Multidrug resistance in European Clostridium difficile clinical isolates.

Authors: Patrizia Spigaglia; Fabrizio Barbanti; Paola Mastrantonio
Journal: J Antimicrob Chemother Date: 2011-07-19 Impact factor: 5.790

6. The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999-2007.

Authors: Aron J Hall; Aaron T Curns; L Clifford McDonald; Umesh D Parashar; Ben A Lopman
Journal: Clin Infect Dis Date: 2012-04-04 Impact factor: 9.079

Ceftolozane-tazobactam activity against phylogenetically diverse Clostridium difficile strains.

1. Development and evaluation of a novel, semiautomated Clostridium difficile typing platform.

Review 2. The changing epidemiology of Clostridium difficile infections.

3. Antimicrobial-resistant strains of Clostridium difficile from North America.

4. Impact of clinical symptoms on interpretation of diagnostic assays for Clostridium difficile infections.

5. Multidrug resistance in European Clostridium difficile clinical isolates.

6. The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999-2007.

7. A systematic evaluation of methods to optimize culture-based recovery of Clostridium difficile from stool specimens.

8. Clostridium difficile--associated disease in a setting of endemicity: identification of novel risk factors.

9. Activity of ceftolozane-tazobactam against a broad spectrum of recent clinical anaerobic isolates.

Review 10. Burden of Clostridium difficile on the healthcare system.